Qihui Jin

USPTO Granted Patents = 7 (Patent Applications = 5)

EPO Patents = 2 (Patent Applications = 9)

Average Co-Inventor Count = 3.6

ph-index = 3

Forward Citations = 43(Granted Patents)

Company Filing History:

Nexys Therapeutics, Inc.

Years Active: 2011-2025

Loading Chart...

7 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12371408 - Aryl hydrocarbon receptor agonists and uses thereof (2025-07-29),

2. 12168646 - Aryl hydrocarbon receptor agonists and uses thereof (2024-12-17),

3. 12102626 - (Pyridin-2-yl)amine derivatives as TGF-BETA R1 (ALK5) inhibitors for the treatment of cancer (2024-10-01),

4. 11458138 - 6-6 fused bicyclic heteroaryl compounds and their use as LATS inhibitors (2022-10-04),

5. 8546370 - Compounds and compositions as kinase inhibitors (2013-10-01),

6. 8354526 - Pyrido [4, 3-D] pyrimidinone derivatives as kinase inhibitors (2013-01-15),

7. 7928133 - Compounds and compositions as hedgehog signaling pathway modulators (2011-04-19),

Title: **Innovator Qihui Jin: Pioneering Pharmaceutical Advances from San Diego**

Introduction

Qihui Jin, an accomplished inventor based in San Diego, California, has made significant contributions to the pharmaceutical field. With a total of six patents to his name, Qihui's work focuses on developing innovative therapeutic solutions aimed at treating various health conditions.

Latest Patents

Among his noteworthy innovations is a patent for "Aryl hydrocarbon receptor agonists and uses thereof." This invention pertains to pharmaceutical compounds designed to modulate the activity of the aryl hydrocarbon receptor (AhR). These compounds are particularly beneficial in addressing inflammatory conditions within the intestinal tract and central nervous system disorders influenced by the gut-brain axis, including diseases such as inflammatory bowel disease (IBD), ulcerative colitis, Crohn's disease, Huntington's disease, and multiple sclerosis.

Another significant patent held by Qihui Jin is for "(Pyridin-2-yl)amine derivatives as TGF-BETA R1 (ALK5) inhibitors for the treatment of cancer." This invention encompasses pharmaceutical compositions and methods aimed at treating or preventing proliferation disorders related to TGFβR1 activity, including cancers and fibrosis. The compounds described have specific structural features that enhance their effectiveness in targeting tissues and organs affected by these diseases.

Career Highlights

Qihui Jin has been associated with reputable companies such as Irm LLC and Nexys Therapeutics, Inc., where he has contributed his expertise to advance pharmaceutical research and development. His work within these organizations has enabled him to focus on creating innovative therapies with real-world applications.

Collaborations

Throughout his career, Qihui has collaborated with other talented individuals, including Qiang Ding and Yahua Liu. These partnerships have facilitated the exchange of ideas and knowledge, further enriching his contributions to the field of pharmaceutical innovations.

Conclusion

Qihui Jin is an exemplary figure in the realm of pharmaceutical inventions, with a clear commitment to improving health outcomes through innovative solutions. His patents reflect a deep understanding of the complexities of human health and a dedication to addressing significant medical challenges. As he continues to push the boundaries of scientific discovery, the impact of his work is likely to resonate in the pharmaceutical industry for years to come.

This text is generated by artificial intelligence and may not be accurate.